Pharmacology of cardiac arrest and reperfusion

Cardiac Arrest: The Science and Practice of Resuscitation Medicine

Volumn 9780521847001, Issue , 2007, Pages 395-416

  Pellis, Tommaso ^a   Soar, Jasmeet ^b   Perkins, Gavin ^c   Gazmuri, Raul J ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c North Chicago VA Medical Center ^*  (United Kingdom)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952325149     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544828.022     Document Type: Chapter

References (181)

1. von Planta, M., von Planta, I., Wagner, O. Et al. Adenosine during cardiac arrest and cardiopulmonary resuscitation: A placebo-controlled, randomized trial. Crit. Care Med. 1992; 20(5): 645-649.
2. Tang, W., Weil, M.H., Sun, S. Et al. K(ATP) channel activation reduces the severity of postresuscitation myocardial dys-function. Am. J. Physiol. Heart Circ. Physiol. 2000; 279(4): H1609-H1615.
3. Ayoub, I.M., Kolarova, J., Yi, Z. Et al. Sodium-hydrogen exchange inhibition during ventricular fibrillation: Beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resus-citability. Circulation 2003; 107(13): 1804-1809.
4. Kaye, W., Mancini, M.E., & Rallis, S.F. Can better basic and advanced cardiac life support improve outcome from cardiac arrest? Crit. Care Med. 1985; 13(11): 916-920.
5. Gazmuri, R.J., Ayoub, I.M., & Kolarova, J. Myocardial protec-tion during resuscitation from cardiac arrest. Curr. Opin. Crit. Care. 2003; 9(3): 199-204.
6. Bunch, T.J., White, R.D., Gersh, B.J. Et al. Long-term outcomes of out-of-hospital cardiac arrest after successful early defib-rillation. N. Engl. J. Of Med. 2003; 348(26): 2626-2633.
7. Bunch, T.J., White, R.D., Gersh, B.J. Et al. Hypothermia after Cardiac Arrest Study Group. Mild thera-peutic hypothermia to improve the neurologic outcome after cardiac arrest. N. Engl. J. Med. 2002; 346(8): 549-556.
8. Gonzalez, E.R. Pharmacologic controversies in CPR. Ann. Emerg. Med. 1993; 22(2): 317-323.
9. Paret, G., Mazkereth, R., Sella, R. Et al. Atropine pharmacoki-netics and pharmacodynamics following endotracheal versus endobronchial administration in dogs. Resuscitation 1999; 41(1): 57-62.
10. Grillo, J.A., Venitz, J., & Ornato, J.P. Prediction of lidocaine tissue concentrations following different dose regimes during cardiac arrest using a physiologically based pharma-cokinetic model. Resuscitation 2001; 50(3): 331-340.
11. Michael, J.R., Guerci, A.D., Koehler, R.C. Et al. Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 1984; 69(4): 822-835.
12. Duggal, C., Weil, M.H., Gazmuri, R.J. Et al. Regional blood flow during closed-chest cardiac resuscitation in rats. J. Appl. Physiol. 1993; 74(1): 147-152.
13. Voorhees, W.D., Babbs, C.F., & Tacker, W.A., Jr. Regional blood flow during cardiopulmonary resuscitation in dogs. Crit. Care Med. 1980; 8(3): 134-136.
14. Thrush, D.N., Downs, J.B., & Smith, R.A. Is epinephrine contraindicated during cardiopulmonary resuscitation? Circulation 1997; 96(8): 2709-2714.
15. Wenzel, V., Lindner, K.H., Prengel, A.W. Et al. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcountershock pulseless electrical activity in pigs. Crit. Care Med. 1999; 27(3): 486-492.
16. Gudipati, C.V., Weil, M.H., Bisera, J. Et al. Expired carbon dioxide: A noninvasive monitor of cardiopulmonary resusci-tation. Circulation 1988; 77(1): 234-239.
17. Rubertsson, S., & Wiklund, L. Hemodynamic effects of epi-nephrine in combination with different alkaline buffers during experimental, open-chest, cardiopulmonary resusci-tation. Crit. Care Med. 1993; 21(7): 1051-1057.
18. Hornchen, U., Schuttler, J., & Stoeckel, H. Influence of the pulmonary circulation on adrenaline pharmacokinetics during cardiopulmonary resuscitation. Eur. J. Anaesthesiol. 1992; 9(1): 85-91.
19. Stiell, I.G., Wells, G.A., Field, B. Et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N. Engl. J. Med. 2004; 351(7): 647-656.
20. Holmberg, M., Holmberg, S., & Herlitz, J. Low chance of sur-vival among patients requiring adrenaline (epinephrine) or intubation after out-of-hospital cardiac arrest in Sweden. Resuscitation 2002; 54(1): 37-45.
21. Dorian, P., Cass, D., Schwartz, B. Et al. Amiodarone as com-pared with lidocaine for shock-resistant ventricular fibrilla-tion. N. Engl. J. Med. 2002; 346(12): 884-890.
22. Wenzel, V., Krismer, A.C., Arntz, H.R. Et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopul-monary resuscitation. N. Engl. J. Med. 2004; 350(2): 105-113.
23. Stiell, I.G., Wells, G.A., Hebert, P.C. Et al. Association of drug therapy with survival in cardiac arrest: Limited role of advanced cardiac life support drugs. Acad. Emerg. Med. 1995; 2(4): 264-273.
24. Kudenchuk, P.J., Cobb, L.A., Copass, M.K. Et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N. Engl. J. Med. 1999; 341(12): 871-878.
25. Nolan, J.P., Deakin, C.D., Soar, J. Et al. European Resuscitation Council guidelines for resuscitation 2005. Section 4. Adult advanced life support. Resuscitation 2005; 67 Suppl 1: S39-S86.
26. Nolan, J.P., Deakin, C.D., Soar, J. Et al. 2005 American Heart Association Guidelines for Cardiopul-monary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112(24 Suppl): IV1-IV203.
27. Sharff, J.A., Pantley, G., & Noel, E. Effect of time on regional organ perfusion during two methods of cardiopulmonary resuscitation. Ann. Emerg. Med. 1984; 13(9 Pt 1): 649-656.
28. Klouche, K., Weil, M.H., Sun, S. Et al. Evolution of the stone heart after prolonged cardiac arrest. Chest. 2002; 122(3): 1006-1011.
29. Apfelbaum, J.L., Gross, J.B., & Schaw, L.M. Changes in lido-caine protein binding may explain its increased CNS toxicity at elevated CO2 tensions. Anesthesiology. 1984; 61(3A): Abstract 213.
30. Pentel, P., & Benowitz, N. Pharmacokinetic and pharmacody-namic considerations in drug therapy of cardiac emergen-cies. Clin. Pharmacokinet. 1984; 9(4): 273-308.
31. Doan, L.A. Peripheral versus central venous delivery of med-ications during CPR. Ann. Emerg. Med. 1984; 13(9 Pt 2): 784-786.
32. Barsan, W.G., Levy, R.C., & Weir, H. Lidocaine levels during CPR: Differences after peripheral venous, central venous, and intracardiac injections. Ann. Emerg. Med. 1981; 10(2): 73-78.
33. Kuhn, G.J., White, B.C., Swetnam, R.E. Et al. Peripheral vs central circulation times during CPR: A pilot study. Ann. Emerg. Med. 1981; 10(8): 417-419.
34. Hedges, J.R., Barsan, W.B., Doan, L.A. Et al. Central versus peripheral intravenous routes in cardiopulmonary resuscita-tion. Am. J. Emerg. Med. 1984; 2(5): 385-390.
35. Redding, J.S., Asuncion, J.S., & Pearson, J.W. Effective routes of drug administration during cardiac arrest. Anesth Analg. 1967; 46(2): 253-258.
36. Hearse, D.J. Myocardial protection during ischemia and reperfusion. Mol. Cell. Biochem. 1998; 186: 177-184.
37. Redding, J.S., & Pearson, J.W. Evaluation of drugs for cardiac resuscitation. Anesthesiology 1963; 24: 203-207.
38. Ditchey, R., & Lindenfeld, J. Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during closed-chest resuscitation in dogs. Circulation 1988; 78: 382-389.
39. Pellis, T., Weil, M.H., Tang, W. Et al. Evidence favoring the use of an [alpha]2-selective vasopressor agent for cardiopul-monary resuscitation. Circulation 2003; 108(21): 2716-2721.
40. Koretsune, Y., & Marban, E. Mechanism of ischemic contrac-ture in ferret hearts: Relative roles of [Ca2+]i elevation and ATP depletion. Am. J. Physiol. 1990; 258(1 Pt 2): H9-H16.
41. Klouche, K., Weil, M.H., Sun, S. Et al. Stroke volumes gener-atedbyprecordialcompressionduringcardiacresuscitation. Crit. Care Med. 2002; 30(12): 2626-2631.
42. Takino, M., & Okada, Y. Firm myocardium in cardiopul-monary resuscitation. Resuscitation 1996; 33(2): 101-106.
43. Hossmann, K.A., & Zimmermann, V. Resuscitation of the monkey brain after 1 h complete ischemia, I: Physiological and morphological observations. Brain Res. 1974; 81(1): 59-74.
44. Kleihues, P., Hossmann, K.A., Pegg, A.E. Et al. Resuscitation of the monkey brain after one hour complete ischemia, III: Indications of metabolic recovery. Brain Res. 1975; 95(1): 61-73.
45. Kirsch, J.R., Dean, J.M., & Rogers, M.C. Current concepts in brain resuscitation. Arch. Intern. Med. 1986; 146(7): 1413-1419.
46. Angelos, M., Safar, P., & Reich, H. A comparison of car-diopulmonary resuscitation with cardiopulmonary bypass after prolonged cardiac arrest in dogs: Reperfusion pressures and neurologic recovery. Resuscitation 1991; 21(2-3): 121-135.
47. Opie, L.H. Effects of regional ischemia on metabolism of glucose and fatty acids. Relative rates of aerobic and anaero-bic energy production during myocardial infarction and com-parison with effects of anoxia. Circ. Res. 1976; 38(5 Suppl 1): I52-174.
48. Theroux, P. Protection of the myocardial cell during ischemia. Am. J. Cardiol. 1999; 83(10A): 3G-9G.
49. Hearse, D.J. Oxygen deprivation and early myocardial con-tractile failure: A reassessment of the possible role of adeno-sine triphosphate. Am. J. Cardiol. 1979; 44(6): 1115-1121.
50. Reimer, K.A., Hill, M.L., & Jennings, R.B. Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J. Mol. Cell. Cardiol. 1981; 13(2): 229-239.
51. Monroe, R.G., & French, G. Ventricular pressure-volume rela-tionships and oxygen consumption in fibrillation and arrest. Circ. Res. 1960; 8: 260-266.
52. Hashimoto, K., Shigei, T., Imai, S. Et al. Oxygen consumption and coronary vascular tone in the isolated fibrillating dog heart. Am. J. Physiol. 1960; 198: 965-970.
53. Paradis, N.A., Martin, G.B., Rivers, E.P. Et al. Coronary perfu-sion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. J. Am. Med. Assoc. 1990; 263(8): 1106-1113.
54. Sundt, T.M., Jr., Sharbrough, F.W., Piepgras, D.G. Et al. Correlation of cerebral blood flow and electroencephalo-graphic changes during carotid endarterectomy: With results of surgery and hemodynamics of cerebral ischemia. Mayo Clin. Proc. 1981; 56(9): 533-543.
55. Branston, N.M., Strong, A.J., & Symon, L. Extracellular potas-sium activity, evoked potential and tissue blood flow. Relationships during progressive ischaemia in baboon cere-bral cortex. J. Neurol Sci. 1977; 32(3): 305-321.
56. Niemann, J.T. Differences in cerebral and myocardial per-fusion during closed-chest resuscitation. Ann. Emerg. Med. 1984; 13(9 Pt 2): 849-853.
57. Ralston, S.H., Voorhees, W.D., & Babbs, C.F. Intrapulmonary epinephrine during prolonged cardiopulmonary resuscita-tion: Improved regional blood flow and resuscitation in dogs. Ann. Emerg. Med. 1984; 13(2): 79-86.
58. Ditchey, R.V., Winkler, J.V., & Rhodes, C.A. Relative lack of coronary blood flow during closed-chest resuscitation in dogs. Circulation 1982; 66(2): 297-302.
59. Lee, S.K., Vaagenes, P., Safar, P. Et al. Effect of cardiac arrest time on cortical cerebral blood flow during subsequent standard external cardiopulmonary resuscitation in rabbits. Resuscitation 1989; 17(2): 105-117.
60. Klocke, F.J., & Ellis, A.K. Control of coronary blood flow. Annu. Rev. Med. 1980; 31: 489-508.
61. Cobb, L.A., Fahrenbruch, C.E., Walsh, T.R. Et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. J. Am. Med. Assoc. 1999; 281(13): 1182-1188.
62. Pearson, J.W., & Redding, J.S. Peripheral vascular tone on cardiac resuscitation. Anesth. Analg. 1965; 44(6): 746-752.
63. Pearson, J.W., & Redding, J.S. The role of epinephrine in cardiac resuscitation. Anesth. Analg. 1963; 42: 599-606.
64. Pearson, J.W., & Redding, J.S. Epinephrine in cardiac resusci-tation. Am. Heart J. 1963; 66: 210-214.
65. Kern, K.B., Ewy, G.A., Voorhees, W.D. Et al. Myocardial per-fusion pressure: A predictor of 24-hour survival during pro-longed cardiac arrest in dogs. Resuscitation 1988; 16: 241-250.
66. Sanders, A.B., Ewy, G.A., & Taft, T.V. Prognostic and therapeu-tic importance of the aortic diastolic pressure in resuscitation from cardiac arrest. Crit. Care Med. 1984; 12(10): 871-873.
67. Sanders, A.B., Ogle, M., & Ewy, G.A. Coronary perfusion pres-sure during cardiopulmonary resuscitation. Am. J. Emerg. Med. 1985; 3(1): 11-14.
68. Jordan, J.E., Zhao, Z.Q., & Vinten-Johansen, J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 1999; 43(4): 860-878.
69. Tranum-Jensen, J., Janse, M.J., Fiolet, W.T. Et al. Tissue osmo-lality, cell swelling, and reperfusion in acute regional myocar-dial ischemia in the isolated porcine heart. Circ. Res. 1981; 49(2): 364-381.
70. Karmazyn, M. Amiloride enhances postischemic ventricular recovery: Possible role of Na+-H+ exchange. Am. J. Physiol. 1988; 255(3 Pt 2): H608-H615.
71. Lazdunski, M., Frelin, C., & Vigne, P. The sodium/hydrogen exchange system in cardiac cells: Its biochemical and phar-macological properties and its role in regulating internal con-centrations of sodium and internal pH. J. Mol. Cell. Cardiol. 1985; 17(11): 1029-1042.
72. Avkiran, M. Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. Am. J. Cardiol. 1999; 83(10A): 10G-17G; discussion 17G-18G.
73. Imahashi, K., Kusuoka, H., Hashimoto, K. Et al. Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res. 1999; 84(12): 1401-1406.
74. Mosca, S.M., & Cingolani, H.E. Comparison of the protective effects of ischemic preconditioning and the Na+/H+ exchanger blockade. Naunyn Schmiedebergs Arch. Pharmacol. 2000; 362(1): 7-13.
75. Mosca, S.M., & Cingolani, H.E. [The Na+/Ca2+ exchanger as responsible for myocardial stunning]. Medicina (B Aires). 2001; 61(2): 167-173.
76. Gazmuri, R.J., Ayoub, I.M., Hoffner, E. Et al. Successful ven-tricular defibrillation by the selective sodium-hydrogen exchanger isoform-1 inhibitor cariporide. Circulation 2001; 104(2): 234-239.
77. Gazmuri, R.J., Hoffner, E., Kalcheim, J. Et al. Myocardial pro-tection during ventricular fibrillation by reduction of proton-driven sarcolemmal sodium influx. J. Lab. Clin. Med. 2001; 137(1): 43-55.
78. Roden, D.M. The principles of drug therapy. In Zipes, D.P., Libby, P., Bonow, R.O. Et al., eds. Heart Disease. 7th edn. Philadephia: Elsevier Saunders; 2005: 43-52.
79. Roden, D.M., & George, A.L., Jr. The genetic basis of variabil-ity in drug responses. Nat. Rev. Drug Discov. 2002; 1(1): 37-44.
80. Evans, W.E., & Relling, M.V. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487-491.
81. Roses, A.D. Pharmacogenetics and the practice of medicine. Nature 2000; 405(6788): 857-865.
82. Meyer, U.A. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-1671.
83. Collins, F.S., & Jegalian, K.G. Deciphering the code of life. Sci. Am. 1999; 281(6): 86-91.
84. Collins, F.S. Shattuck lecture-medical and societal con-sequences of the Human Genome Project. N. Engl. J. Med. 1999; 341(1): 28-37.
85. Banerjee, S., Singhi, S.C., Singh, S. Et al. The intraosseous route is a suitable alternative to intravenous route for fluid resuscitation in severely dehydrated children. Ind. Pediatr. 1994; 31(12): 1511-1520.
86. Brickman, K.R., Krupp, K., Rega, P. Et al. Typing and screening of blood from intraosseous access. Ann. Emerg. Med. 1992; 21(4): 414-417.
87. Fiser, R.T., Walker, W.M., Seibert, J.J. Et al. Tibial length follow-ing intraosseous infusion: A prospective, radiographic analy-sis. Pediatr Emerg Care. 1997; 13(3): 186-188.
88. Ummenhofer, W., Frei, F.J., Urwyler, A. Et al. Are laboratory values in bone marrow aspirate predictable for venous blood in paediatric patients? Resuscitation 1994; 27(2): 123-128.
89. Glaeser, P.W., Hellmich, T.R., Szewczuga, D. Et al. Five-year experience in prehospital intraosseous infusions in children and adults. Ann. Emerg. Med. 1993; 22(7): 1119-1124.
90. Guy, J., Haley, K., & Zuspan, S.J. Use of intraosseous infusion in the pediatric trauma patient. J. Pediatr. Surg. 1993; 28(2): 158-161.
91. Macnab, A., Christenson, J., Findlay, J. Et al. A new system for sternal intraosseous infusion in adults. Prehosp. Emerg. Care. 2000; 4(2): 173-177.
92. Ellemunter, H., Simma, B., Trawoger, R. Et al. Intraosseous lines in preterm and full term neonates. Arch. Dis. Child. Fetal Neonatal Ed. 1999; 80(1): F74-F75.
93. Guengerich, F.P. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 1-17.
94. Meyer, U.A., & Zanger, U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 1997; 37: 269-296.
95. Weinshilboum, R.M., Otterness, D.M., & Szumlanski, C.L. Methylation pharmacogenetics: Catechol O-methyltrans-ferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 19-52.
96. Innocenti, F., Iyer, L., & Ratain, M.J. Pharmacogenetics: A tool for individualizing antineoplastic therapy. Clin. Pharmacokinet. 2000; 39(5): 315-325.
97. Quintana, M., Kahan, T., & Hjemdahl, P. Pharmacological pre-vention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent. Am. J. Cardiovasc. Drugs. 2004; 4(3): 159-167.
98. Conrad, K.A., Byers, J.M., 3rd, Finley, P.R. Et al. Lidocaine elim-ination: Effects of metoprolol and of propranolol. Clin. Pharmacol. Ther. 1983; 33(2): 133-138.
99. Ochs, H.R., Carstens, G., & Greenblatt, D.J. Reduction in lido-caine clearance during continuous infusion and by coad-ministration of propranolol. N. Engl. J. Med. 1980; 303(7): 373-377.
100. Wing, L.M., Miners, J.O., Birkett, D.J. Et al. Lidocaine disposi-tion-sex differences and effects of cimetidine. Clin. Pharmacol. Ther. 1984; 35(5): 695-701.
101. Yang, T., & Roden, D.M. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996; 93(3): 407-411.
102. Fiset, C., Drolet, B., Hamelin, B.A. Et al. Block of IKs by the diuretic agent indapamide modulates cardiac electrophysio-logical effects of the class III antiarrhythmic drug dl-sotalol. J. Pharmacol. Exp. Ther. 1997; 283(1): 148-156.
103. Lee, J.T., Kroemer, H.K., Silberstein, D.J. Et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N. Engl. J. Med. 1990; 322(25): 1764-1768.
104. Kalow, W. Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin Pharmacol Ther. 2001; 70(1): 1-4.
105. McLeod, H.L., & Evans, W.E. Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 101-121.
106. Kuehl, P., Zhang, J., Lin, Y. Et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001; 27(4): 383-391.
107. Wandel, C., Witte, J.S., Hall, J.M. Et al. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin. Pharmacol. Ther. 2000; 68(1): 82-91.
108. Schuetz, E.G., Strom, S., Yasuda, K. Et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 2001; 276(42): 39411-39418.
109. Sofowora, G.G., Dishy, V., Muszkat, M. Et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin. Pharmacol. Ther. 2003; 73(4): 366-371.
110. Dishy, V., Sofowora, G.G., Xie, H.G. Et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 2001; 345(14): 1030-1035.
111. Johnson, J.A., & Terra, S.G. Beta-adrenergic receptor poly-morphisms: Cardiovascular disease associations and phar-macogenetics. Pharm Res. 2002; 19(12): 1779-1787.
112. Yang, P., Kanki, H., Drolet, B. Et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105(16): 1943-1948.
113. Sesti, F., Abbott, G.W., Wei, J. Et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. USA 2000; 97(19): 10613-10618.
114. Mitcheson, J.S., Chen, J., Lin, M. Et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA 2000; 97(22): 12329-12333.
115. Roden, D.M. Taking the “idio” out of “idiosyncratic”: Predict-ing torsades de pointes. Pacing Clin. Electrophysiol. 1998; 21(5): 1029-1034.
116. Donger, C., Denjoy, I., Berthet, M. Et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997; 96(9): 2778-2781.
117. Napolitano, C., Schwartz, P.J., Brown, A.M. Et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol. 2000; 11(6): 691-696.
118. Yang, P. Frequency of ion channel mutations and polymor-phisms in a large population of patients with drug associated Long QT Syndrome. Pacing Clin. Electrophys 2001; 24: 579.
119. Ambudkar, S.V., Dey, S., Hrycyna, C.A. Et al. Biochemical, cel-lular, and pharmacological aspects of the multidrug trans-porter. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 361-398.
120. Zhang, L., Brett, C.M., & Giacomini, K.M. Role of organic cation transporters in drug absorption and elimination. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 431-460.
121. Mayer, U., Wagenaar, E., Dorobek, B. Et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 1997; 100(10): 2430-2436.
122. Aung, K., & Htay, T. Vasopressin for cardiac arrest: A system-atic review and meta-analysis. Arch. Intern. Med. 2005; 165(1): 17-24.
123. Vaknin, Z., Manisterski, Y., Ben-Abraham, R. Et al. Is endotra-cheal adrenaline deleterious because of the beta adrenergic effect? Anesth Analg. 2001; 92(6): 1408-1412.
124. Efrati, O., Ben-Abraham, R., Barak, A. Et al. Endobronchial adrenaline: Should it be reconsidered? Dose response and haemodynamic effect in dogs. Resuscitation 2003; 59(1): 117-122.
125. Kam, P.C., Williams, S., & Yoong, F.F. Vasopressin and terli-pressin: Pharmacology and its clinical relevance. Anaesthesia 2004; 59(10): 993-1001.
126. Wenzel, V., Lindner, K.H., Augenstein, S. Et al. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Crit. Care Med. 1999; 27(8): 1565-1569.
127. Efrati, O., Barak, A., Ben-Abraham, R. Et al. Should vaso-pressin replace adrenaline for endotracheal drug administra-tion? Crit. Care Med. 2003; 31(2): 572-576.
128. Wenzel, V., Lindner, K.H., Prengel, A.W. Et al. Endobronchial vasopressin improves survival during cardiopulmon-ary resuscitation in pigs. Anesthesiology 1997; 86(6): 1375-1381.
129. Lindner, K.H., Prengel, A.W., Pfenninger, E.G. Et al. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 1995; 91(1): 215-221.
130. Biondi-Zoccai, G.G., Abbate, A., Parisi, Q. Et al. Is vasopressin superior to adrenaline or placebo in the management of cardiac arrest? A meta-analysis. Resuscitation 2003; 59(2): 221-224.
131. Lindner, K.H., Prengel, A.W., Brinkmann, A. Et al. Vasopressin administration in refractory cardiac arrest. Ann. Intern. Med. 1996; 124(12): 1061-1064.
132. Lindner, K.H., Dirks, B., Strohmenger, H.U. Et al. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349(9051): 535-537.
133. Stiell, I.G., Hebert, P.C., Wells, G.A. Et al. Vasopressin versus epinephrine for inhospital cardiac arrest: A randomised con-trolled trial. Lancet 2001; 358(9276): 105-109.
134. Singh, B.N., & Vaughan Williams, E.M. The effect of amio-darone, a new antianginal drug, on cardiac muscle. Br. J. Pharmacol. 1970; 39: 657.
135. Smith, W. Mechanisms of cardiac arrhythmias and conduc-tion disturbances. In Hurst, J.W., ed. The Heart, Arteries and Veins. 7th edn. New York, NY: McGraw-Hill Health Professions Division; 1990: 473-488.
136. Pinter, A., & Dorian, P. Intravenous antiarrhythmic agents. Curr. Opin. Cardiol. 2001; 16: 17.
137. Chow, M.S. Intravenous amiodarone: Pharmacology, phar-macokinetics, and clinical use. Ann Pharmacother. 1996; 30: 637.
138. Mitchell, L.B., Wyse, G., Gillis, A.M. Et al. Electropharmaco-logy of amiodarone therapy initiation. Circulation 1989; 80: 34.
139. Holt, D.W., Tucker, G.T., Jackson, P.R. Et al. Amiodarone phar-macokinetics. Am. Heart J. 1983; 106(pt 2)(4): 840-847.
140. Huang, J., Skinner, J.L., Rogers, J.M. Et al. The effects of acute and chronic amiodarone on activation patterns and defibril-lation threshold during ventricular fibrillation in dogs. J. Am. Coll. Cardiol. 2002; 40(2): 375-383.
141. Camus, P., Martin, W.J., & Rosenow, E.C. 3rd. Amiodarone pul-monary toxicity. Clin. Chest Med. 2004; 25(1): 65-75.
142. Lin, C., Ke, X., Cvetanovic, I. Et al. The influence of extracellu-lar acidosis on the effect of IKr Blockers. J. Cardiovasc. Pharmacol. Ther. 2005; 10(1): 67-76.
143. Paiva, E.F., Perondi, M.B., Kern, K.B. Et al. Effect of amio-darone on haemodynamics during cardiopulmonary resus-citation in a canine model of resistant ventricular fibrillation. Resuscitation 2003; 58(2): 203-208.
144. Skrifvars, M.B., Kuisma, M., Boyd, J. Et al. The use of undiluted amiodarone in the management of out-of-hospital cardiac arrest. Acta Anaesthesiol Scand. 2004; 48(5): 582-587.
145. Somberg, J.C., Bailin, S.J., Haffajee, C.I. Et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am. J. Cardiol. 2002; 90(8): 853-859.
146. Somberg, J.C., Timar, S., Bailin, S.J. Et al. Lack of a hypotensive effect with rapid administration of a new aqueous formula-tion of intravenous amiodarone. Am. J. Cardiol. 2004; 93(5): 576-581.
147. Schwarz, B., Mair, P., Wagner-Berger, H. Et al. Neither vaso-pressin nor amiodarone improve CPR outcome in an animal model of hypothermic cardiac arrest. Acta. Anaesthesiol. Scand. 2003; 47(9): 1114-1118.
148. Stoner, J., Martin, G., Omara, K. Et al. Amiodarone and bretylium in the treatment of hypothermic ventricular fibril-lation in a canine model. Acad. Emerg. Med. 2003; 10(3): 187-191.
149. Cannon, L.A., Heiselman, D.E., Dougherty, J.M. Et al. Magnesium levels in cardiac arrest victims: Relationship between magnesium levels and successful resuscitation. Ann. Emerg. Med. 1987; 16(11): 1195-1199.
150. Tobey, R.C., Birnbaum, G.A., Allegra, J.R. Et al. Successful resuscitation and neurologic recovery from refractory ven-tricular fibrillation after magnesium sulfate administration. Ann. Emerg. Med. 1992; 21(1): 92-96.
151. Thel, M.C., Armstrong, A.L., McNulty, S.E. Et al. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet 1997; 350(9087): 1272-1276.
152. Fatovich, D., Prentice, D., & Dobb, G. Magnesium in in-hospital cardiac arrest. Lancet 1998; 351(9100): 446.
153. Allegra, J., Lavery, R., Cody, R. Et al. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehos-pital setting. Resuscitation 2001; 49(3): 245-249.
154. Hassan, T.B., Jagger, C., & Barnett, D.B. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. Emerg. Med. J. 2002; 19(1): 57-62.
155. Miller, B., Craddock, L., Hoffenberg, S. Et al. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: Safety data and recommendations for future studies. Resuscitation 1995; 30(1): 3-14.
156. Longstreth, W.T., Jr., Fahrenbruch, C.E., Olsufka, M. Et al. Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest. Neurology 2002; 59(4): 506-514.
157. Brown, C.G., Griffith, R.F., Neely, D. Et al. The effect of intra-venous magnesium administration on aortic, right atrial and coronary perfusion pressures during CPR in swine. Resuscitation 1993; 26(1): 3-12.
158. Siemkowicz, E. Magnesium sulfate solution dramatically improves immediate recovery of rats from hypoxia. Resuscitation 1997; 35(1): 53-59.
159. Seaberg, D.C., Menegazzi, J.J., Check, B. Et al. Use of a cardio-cerebral-protective drug cocktail prior to countershock in a porcine model of prolonged ventricular fibrillation. Resuscitation 2001; 51(3): 301-308.
160. Zhang, Y., Davies, L.R., Martin, S.M. Et al. Magnesium reduces free radical concentration and preserves left ventricular function after direct current shocks. Resuscitation 2003; 56(2): 199-206.
161. Bottiger, B.W., Bode, C., Kern, S. Et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopul-monary resuscitation: A prospective clinical trial. Lancet 2001; 357(9268): 1583-1585.
162. Lederer, W., Lichtenberger, C., Pechlaner, C. Et al. Recombinant tissue plasminogen activator during car-diopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. Resuscitation 2001; 50(1): 71-76.
163. Janata, K., Holzer, M., Kurkciyan, I. Et al. Major bleeding com-plications in cardiopulmonary resuscitation: The place of thrombolytic therapy in cardiac arrest due to massive pul-monary embolism. Resuscitation 2003; 57(1): 49-55.
164. Lederer, W., Lichtenberger, C., Pechlaner, C. Et al. Long-term survival and neurological outcome of patients who received recombinant tissue plasminogen activator during out-of-hospital cardiac arrest. Resuscitation 2004; 61(2): 123-129.
165. Scholz, K.H., Hilmer, T., Schuster, S. Et al. Thrombolysis in resuscitated patients with pulmonary embolism. Dtsch. Med. Wochenschr. 1990; 115(24): 930-935.
166. Gramann, J., Lange-Braun, P., Bodemann, T. Et al. Der Einsatz von Thrombolytika in der Reanimation als Ultima ratio zur Uberwindung des Herztodes. Intensiv.-und Notfallbehandlung. 1991; 16(3): 134-137.
167. Tiffany, P.A., Schultz, M., & Stueven, H. Bolus thrombolytic infusions during CPR for patients with refractory arrest rhythms: Outcome of a case series. Ann. Emerg. Med. 1998; 31(1): 124-126.
168. Ruiz-Bailen, M., Aguayo-de-Hoyos, E., Serrano-Corcoles, M.C. Et al. Thrombolysis with recombinant tissue plasmino-gen activator during cardiopulmonary resuscitation in fulmi-nant pulmonary embolism. A case series. Resuscitation 2001; 51(1): 97-101.
169. Abu-Laban, R.B., Christenson, J.M., Innes, G.D. Et al. Tissue plasminogen activator in cardiac arrest with pulseless electri-cal activity. N. Engl. J. Med. 2002; 346(20): 1522-1528.
170. Lin, S.R., Oconnor, M.J., Fischer, H.W. Et al. The effect of combined dextran and streptokinase on cerebral function and blood flow after cardiac arrest: And experimental study on the dog. Invest Radiol. 1978; 13(6): 490-498.
171. Fischer, M., Bottiger, B.W., Popov-Cenic, S. Et al. Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: An experimental study in the cat. Inten. Care Med. 1996; 22(11): 1214-1223.
172. Schreiber, W., Gabriel, D., Sterz, F. Et al. Thrombolytic therapy after cardiac arrest and its effect on neurological outcome. Resuscitation 2002; 52(1): 63-69.
173. Engdahl, J., Abrahamsson, P., Bang, A. Et al. Is hospital care of major importance for outcome after out-of-hospital cardiac arrest? Experience acquired from patients with out-of-hospital cardiac arrest resuscitated by the same Emergency Medical Service and admitted to one of two hospitals over a 16-year period in the municipality of Goteborg. Resuscitation 2000; 43(3): 201-211.
174. Dumot, J.A., Burval, D.J., Sprung, J. Et al. Outcome of adult cardiopulmonary resuscitations at a tertiary referral center including results of “limited” resuscitations. Arch. Intern. Med. 2001; 161(14): 1751-1758.
175. Engdahl, J., Bang, A., Lindqvist, J. Et al. Factors affecting short-and long-term prognosis among 1069 patients with out-of-hospital cardiac arrest and pulseless electrical activity. Resuscitation 2001; 51(1): 17-25.
176. Tortolani, A.J., Risucci, D.A., Powell, S.R. Et al. In-hospital car-diopulmonary resuscitation during asystole. Therapeutic factors associated with 24-hour survival. Chest 1989; 96(3): 622-626.
177. Stueven, H.A., Tonsfeldt, D.J., & Thompson, B.M. Atropine in asystole: Human studies. Ann. Of Emerg. Med. 1984; 13(9 II): 815-817.
178. Sorensen, M., Engbaek, J., Viby-Mogensen, J. Et al. Bradycardia and cardiac asystole following a single injection of suxamethonium. Acta. Anaesthesiol. Scand. 1984; 28(2): 232-235.
179. Coon, G.A., Clinton, J.E., & Ruiz, E. Use of atropine for brady-asystolic prehospital cardiac arrest. Ann. Emerg. Med. 1981; 10(9): 462-467.
180. DeBehnke, D.J., Swart, G.L., Spreng, D. Et al. Standard and higher doses of atropine in a canine model of pulseless elec-trical activity. Acad. Emerg. Med. 1995; 2(12): 1034-1041.
181. Bernheim, A., Fatio, R., Kiowski, W. Et al. Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: An unpredictable and dose-independent phenomenon. Transplantation 2004; 77(8): 1181-1185.